MCO Molecular and Clinical Oncology 2049-9450 2049-9469 D.A. Spandidos 10.3892/mco.2016.847 MCO-0-0-847 Articles HBV X gene point mutations are associated with the risk of hepatocellular carcinoma: A systematic review and meta-analysis WANGYULAN ZENGLI CHENWEIQING Department of Gastroenterology and Respiratory Medicine, Chongqing Cancer Hospital and Institute and Cancer Center, Chongqing 400030, P.R. China Correspondence to: Professor Weiqing Chen, Department of Gastroenterology and Respiratory Medicine, Chongqing Cancer Hospital and Institute and Cancer Center, 181 Hanyu Road, Chongqing 400030, P.R. China, E-mail: chenwq20140809@163.com 06 2016 05 04 2016 4 6 1045 1051 07052015 16112015 Copyright © 2016, Spandidos Publications 2016

Previous evidence suggests that the accumulation of the hepatitis B virus (HBV) X gene region point mutations may be associated with the development of hepatocellular carcinoma (HCC). However, the pathogenesis of HCC remains to be elucidated. The aim of the present meta-analysis was to investigate the association between the HBV X gene point mutations and the risk of HCC. Studies were collected regarding the association between HBV X gene point mutations and the risk of HCC, which were identified in PubMed, EMBASE and China National Knowledge Infrastructure databases. The results were evaluated by use of odds ratios (ORs) and its 95% confidence intervals (CIs), which were pooled by random or fixed effects. A total of 11 studies involving 2,502 patients were included in this meta-analysis. Statistical summary ORs of HBV X gene point mutations were obtained for T1653 (OR, 3.11; 95% CI, 2.22–4.36), V1753 (OR, 2.55; 95% CI, 1.66–3.92), and T1762/A1764 (OR, 4.49; 95% CI, 2.86–7.07). HBV X gene point mutations T1653, V1753 and T1762/A1764 could increase the risk of HCC significantly, particularly the T1762/A1764 double mutations. These mutations may be predictive for hepatocarcinogenesis. However, these results of the meta-analysis should be treated carefully due to a low level of evidence.

 hepatitis B virus X gene hepatocellular carcinoma meta-analysis point mutation Introduction

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide, which is a serious risk to human health (1,2). However, the pathogenesis of HCC has not been fully elucidated. Hepatitis B virus (HBV) chronic infection is considered one of the major risk factors for the development of HCC (3–5).

The HBV genome is an incomplete double-stranded circular structure, containing 4 open reading frames (ORF): S, C, P and X (6,7). ORF region mutations could alter viral replication and virulence force, which lead to a persistent virus infection and severe liver cell damage, and eventually result in the development of HCC (8,9). The precore region encodes the hepatitis B e-antigen (HBeAg), which has been associated with an increased risk of HCC statistically. Certain studies have shown that HBV X gene point mutations can affect the expression of HBeAg and increase the viral replication capacity (8,10,11). In recent years, the association between HBV mutations and the incidence of HCC has focused on the X gene region, the former C gene region and pre-S gene region, and the X gene region is the most important.

Previously, certain studies have identified that the X gene region T1653, V1753, T1762/A1764 and other point mutations may be associated with persistent HBV infection and the development of HCC (6,10–13). However, there remains certain controversy and further research is required. Therefore, the present meta-analysis was performed to investigate the association between HBV X gene point mutations and the development of HCC systematically and comprehensively.

 Materials and methods <sec> <title>Search strategy

Two authors (Wang and Zeng) searched PubMed, EMBASE, the Cochrane Library and Chinese National Knowledge Infrastructure for the relevant studies. The key words included: ‘Hepatitis B virus X gene’, ‘mutation’, ‘liver cancer or hepatocellular carcinoma’. The searches were limited to human subjects. Language restriction was not imposed on the search process. In addition, the reference lists of the included studies were checked manually for other potentially eligible studies. This process was repeated until no additional associated studies could be identified.

 Inclusion criteria

The inclusion criteria included: i) Study design for the prevalence of case-control; ii) the diagnoses of chronic hepatitis B, liver cirrhosis and HCC were according to the guidelines of the American Association for the Study of Liver Diseases (14); iii) all HBsAg-positive patients were infected with HBV >2 years and the HBV DNA level was in accordance with the test standard; and iv) the reported outcomes of patients was HCC.

 Exclusion criteria

The exclusion criteria included: i) Patients with HCV, HDV or human immunodeficiency virus infection; ii) patients with alcoholic liver disease, autoimmune disease or drug-induced liver disease; iii) patients with antiviral treatment; iv) if similar research was reported by the same author, only the recent study or high-quality study was included in this analysis.

 Data extraction and quality evaluation

Data extraction and quality evaluation of studies were conducted by 2 independent authors (Wang and Chen). The extracted data included first author, publication year, country, study design, quality score, cases of patients (number of events and total patients), age, gender, alanine aminotransferase and HBV DNA level, genotypes, mutation sites and detection method. The evaluation standard was in accordance with the methods of the study by Liu et al (15). Discussion or a third investigator aided in solving any disagreements.

 Statistical analysis

The odds ratios (ORs) with 95% confidence intervals (CIs) of binary end points were analyzed. Heterogeneity was checked using χ2 test, P-values and I2. The random effects model was used when P<0.1; otherwise the fixed effects model was used when P≥0.1. Sensitivity analysis was conducted by eliminating one study in turn in the analysis. Potential publication bias was evaluated by visual inspection of the Begg funnel plots in which the log ORs were plotted against their standard errors. All the data were calculated by RevMan 5.0 software (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration).

 Results <sec> <title>Study characteristics

According to the inclusion and exclusion criteria of the literature, 11 studies involving 2,502 patients were included in this meta-analysis, of whom 2,801 had HCC. These studies included 1 study in Chinese and 10 in English (6,11,13,16–23). A detailed flow chart explaining the inclusion of studies is shown in Fig. 1. The extracted information from the studies included: i) The publication year of the studies was between 1999 and 2013; ii) the study design were case-control studies; iii) the countries of the studies included mainland China, Hong Kong, South Korea and Thailand. A summary of the 11 included studies is shown in Table I. The details of the quality criteria based on factors are listed in Table II.

 Meta-analysis

All 11 studies involving 2,502 patients reported that the relevant outcome of the T1653, V1753 and T1762/A1764 point mutations were associated with the risk of HCC. The results of the meta-analysis showed that T1653 (OR, 3.11; 95% CI, 2.22–4.36) (Fig. 2), V1753 (OR, 2.55; 95% CI, 1.66–3.92) (Fig. 3) and T1762/A1764 (OR, 4.49; 95% CI, 2.86–7.07) (Fig. 4) increase the risk of HCC.

 Subgroup analysis

The summary ORs for HBV X gene mutations were explored by HBeAg status, country and quality score. The summary OR of the T1762/A1764 double mutations in HBeAg (+) group were lower compared to the HBeAg (−) group, whereas the T1653 and V1753 mutations were higher. There is no significant difference in the results between subgroup and overall analyses except for the V1753 point mutation for the risk of HCC in patients from Korea. The result suggested that there was no statistically significant associations between the V1753 mutation and the risk of HCC in Korean patients (OR, 1.25; 95% CI, 0.69–2.26) (Table III). The summary ORs for T1653, V1753 and T1762/A1764 increased with decreasing study quality score (Table III).

 Sensitivity analysis and publication bias

The effect of a single study on the overall pooled analyses was investigated by sensitivity analysis to evaluate the heterogeneity of each study. There were no significant influences observed when one study was removed each turn. The funnel plot showed an asymmetrical distribution of these studies, indicating that publication bias existed in these results regarding an association between T1653 (Fig. 5A), V1753 (Fig. 5B) and T1762/A1764 (Fig. 5C) point mutations and the risk of HCC.

 Discussion

Meta-analysis is regarded as a qualitative and quantitative tool to solve those problems that remain controversial in clinical settings. The results of the meta-analysis were the highest level of evidence. The debate on the association between HBV gene mutations and development of HCC is ongoing. Recently, a series of studies on this subject have been published. Therefore, the present meta-analysis was performed and the results showed that T1653, V1753 and T1762/A1764 mutations could significantly increase the risk of HCC, particularly the T1762/A1764 double mutations.

HBV chronic infection is the most important risk factor for the development of HCC (24). Lin et al (25) considered that the transactivation function of the carboxyl terminus of the HBV X protein would regulate HBV DNA replication and transcription of liver cell proliferation and differentiation. As well as T1653, V1753 and T1762/A1764 mutations are all located in the carboxyl terminus region of the HBV X protein. Kim et al (19) suggested that T1653, V1753 and T1762/A1764 mutations would change the sequence of HBV X protein amino acids, further leading to the activation of proto-oncogenes and inactivation of the tumor suppressor gene, eventually causing the occurrence of HBV-related HCC. However, the mechanism of how the point mutations of HBV X gene region affect the biological function of HBV X protein remains to be elucidated in further studies.

Liu et al (15) considered that the HBeAg status would affect the point mutation type of the HBV X gene and development of HCC. Previous studies suggested that the expression of HBeAg is often significantly correlated with immune evasion and acted as an indicator of active viral replication (26,27). In the subgroup analysis, data on the HBeAg status was extracted, which was a potential confounder, and identified that T1762/A1764 double mutations could decrease HBeAg expression. However, a large number of studies showed that T1762/A1764 double mutations could enhance the virus replication. The contradiction indicated that the decrease of HBeAg expression did not equate to an improved development of HCC. Persistent chronic HBV infection may be due to HBV immune escape, which further aggravates the condition of patients and eventually results in HCC (28,29). Li et al (22) reported that T1762/A1764 double mutations could not predict the development of HCC. However, the present study identified that double mutations were more closely associated with the risk of HCC compared to T1653 or V1753 alone. Therefore, the combined mutations could lead to a higher incidence of liver cancer and improve the predictability of HCC.

The present findings showed that the summary ORs for T1653, V1753 and T1762/A1764 were higher in the low-quality compared to the high-quality studies. Potential confounders may have an important role in evaluating HBV mutations and the risk of HCC in low-quality studies. Yin et al (30) suggested that the average age of the patients with chronic hepatitis B was 10 years younger than that of the patients with HCC. Additionally, Yang et al (31) suggested that HBV mutations accumulated with increasing age. Therefore, the association between the HBV X gene point mutations and risk of HCC was more likely to be overestimated in the confounder-unmatched, low-quality studies.

The main characteristics embodied in the present study were: i) The association between HBV X gene mutations and development of HCC among various studies examined systematically and comprehensively, in order to have an improved understanding for the effect of HBV X protein on development of HCC; ii) a series of subgroup analyses were conducted to explore the effect of potential confounding factors on the development of HCC; and iii) the results suggested that these point mutations could be used as molecular markers of the risk of HCC. The limitations of the study were: i) The age, gender, genotype and other confounding factors could not be matched fully and the existence of various offsets requires further information and data to be confirmed; ii) only 3 HBV X gene mutations were analyzed in the meta-analysis, and there may be other gene mutations that affect the HBV X protein biological function as well as V1674, T1766 and A1768 mutations; and iii) the included studies were all observational case-control studies, as experimental studies could not be conducted in humans.

In the future, the mechanism of the HBV X gene region point mutations should focus on the biological function of the HBV X protein and the association with the development of HCC. In order to improve the prediction for HCC risk and reduce or even avoid the development of HCC, quicker and easier methods should be developed for the detection of HBV gene mutations.

 Acknowledgements

The authors would like to thank Dr Longkun Li for providing methods of data analysis.

 References CazzagonNTrevisaniFMaddaloGItalian Liver Cancer (ITA.LI.CA) Group: Rise and fall of HCV-related hepatocellular carcinoma in Italy: A long-term survey from the ITA.LI.CA centresLiver Int3314201427201310.1111/liv.1220823758775 FaresNPeronJMEpidemiology, natural history, and risk factors of hepatocellular carcinomaRev Prat63216217220–2122013(In French)23513788 MatsudaYIchidaTImpact of hepatitis B virus X protein on the DNA damage response during hepatocarcinogenesisMed Mol Morphol42138142200910.1007/s00795-009-0457-819784739 RawatSClippingerAJBouchardMJModulation of apoptotic signaling by the hepatitis B virus X proteinViruses429452972201210.3390/v411294523202511 BouchardMJNavas-MartinSHepatitis B and C virus hepatocarcinogenesis: Lessons learned and future challengesCancer Lett305123143201110.1016/j.canlet.2010.11.01421168955 KimJKChangHYLeeJMBaatarkhuuOYoonYJParkJYKimYHanKHChonCYAhnSHSpecific mutations in the enhancer II/core promoter/precore regions of hepatitis B virus subgenotype C2 in Korean patients with hepatocellular carcinomaJ Med Virol8110021008200910.1002/jmv.2150119382267 LiuLLiYZhangSYuDZhuMHepatitis B virus X protein mutant upregulates CENP-A expression in hepatoma cellsOncol Rep27168173201221956590 TuHBonuraCGianniniCMoulyHSoussanPKewMPaterlini-BréchotPBréchotCKremsdorfDBiological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissuesCancer Res6178037810200111691796 YehCTShenCHTaiDIChuCMLiawYFIdentification and characterization of a prevalent hepatitis B virus X protein mutant in Taiwanese patients with hepatocellular carcinomaOncogene1952135220200010.1038/sj.onc.120390311077437 KanekoMUchidaTMoriyamaMArakawaYShikataTGotohKMimaSProbable implication of mutations of the X open reading frame in the onset of fulminant hepatitis BJ Med Virol47204208199510.1002/jmv.18904703048551270 ShiWWangQZhaoXZhaoLStudy on the relationship between the mutations of hepatitis B virus X gene and precore gene, related factors and hepatocellular carcinomaChinas Med8167347772013(In Chinese) UchidaTSaitohTShinzawaHMutations of the X region of hepatitis B virus and their clinical implicationsPathol Int47183193199710.1111/j.1440-1827.1997.tb04479.x9103208 ShinkaiNTanakaYItoKMukaideMHasegawaIAsahinaYIzumiNYatsuhashiHOritoEJohTInfluence of hepatitis B virus X and core promoter mutations on hepatocellular carcinoma among patients infected with subgenotype C2J Clin Microbiol4531913197200710.1128/JCM.00411-0717652471 CabibboGAntonucciMGencoCUpdate on new approaches in the management of hepatocellular carcinomaHepat Med2163173201010.2147/HMER.S713224367214 LiuSZhangHGuCYinJHeYXieJCaoGAssociations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: A meta-analysisJ Natl Cancer Inst10110661082200910.1093/jnci/djp18019574418 TakahashiKOhtaYKanaiKAkahaneYIwasaYHinoKOhnoNYoshizawaHMishiroSClinical implications of mutations C-to-T1653 and T-to-C/A/G1753 of hepatitis B virus genotype C genome in chronic liver diseaseArch Virol14412991308199910.1007/s00705005058810481738 TanakaYMukaideMOritoEYuenMFItoKKurbanovFSugauchiFAsahinaYIzumiNKatoMSpecific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinomaJ Hepatol45646653200610.1016/j.jhep.2006.06.01816935384 WangZTanakaYHuangYKurbanovFChenJZengGZhouBMizokamiMHouJClinical and virological characteristics of hepatitis B virus subgenotypes Ba, C1 and C2 in ChinaJ Clin Microbiol4514911496200710.1128/JCM.02157-0617376881 KimHJParkJHJeeYLeeSAKimHSongBCYangSLeeMYoonJHKimYJHepatitis B virus X mutations occurring naturally associated with clinical severity of liver disease among Korean patients with chronic genotype C infectionJ Med Virol8013371343200810.1002/jmv.2121918551606 ChoiCSChoEYParkRKimSJChoJHKimHCX gene mutations in hepatitis B patients with cirrhosis, with and without hepatocellular carcinomaJ Med Virol8117211725200910.1002/jmv.2159119697408 TangkijvanichPSa-NguanmooPMahachaiVTheamboonlersAPoovorawanYA case-control study on sequence variations in the enhancer II/core promoter/precore and X genes of hepatitis B virus in patients with hepatocellular carcinomaHepatol Int4577584201010.1007/s12072-010-9197-z21063480 LiWChenGYuXShiYPengMWeiJAccumulation of the mutations in basal core promoter of hepatitis B virus subgenotype C1 increase the risk of hepatocellular carcinoma in Southern ChinaInt J Clin Exp Pathol610761085201323696925 LyuHLeeDChungYHKimJALeeJHJinYJParkWMathewsPJaffeeEZhengLSynergistic effects of A1896, T1653 and T1762/A1764 mutations in genotype c2 hepatitis B virus on development of hepatocellular carcinomaJ Viral Hepat20219224201310.1111/j.1365-2893.2012.01654.x23383661 HuangXHollingerFBOccult hepatitis B virus infection and hepatocellular carcinoma: A systematic reviewJ Viral Hepat21153162201410.1111/jvh.1222224438677 LinCLChenJDLiuCJLeePHChenPJLaiMYKaoJHChenDSClinicopathological differences between hepatitis B viral genotype B- and C-related resectable hepatocellular carcinomaJ Viral Hepat146469200710.1111/j.1365-2893.2006.00776.x17212646 KayAZoulimFHepatitis B virus genetic variability and evolutionVirus Res127164176200710.1016/j.virusres.2007.02.02117383765 YimHJLokASNatural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005Hepatology43Suppl 1S173S181200610.1002/hep.2095616447285 JammehSTavnerFWatsonRThomasHCKarayiannisPEffect of basal core promoter and pre-core mutations on hepatitis B virus replicationJ Gen Virol89901909200810.1099/vir.0.83468-018343830 BuckwoldVEXuZChenMYenTSOuJHEffects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replicationJ Virol705845585119968709203 YinJZhangHLiCGaoCHeYZhaiYZhangPXuLTanXChenJRole of hepatitis B virus genotype mixture, subgenotypes C2 and B2 on hepatocellular carcinoma: Compared with chronic hepatitis B and asymptomatic carrier state in the same areaCarcinogenesis2916851691200810.1093/carcin/bgm30118192693 YangHIYehSHChenPJIloejeUHJenCLSuJWangLYLuSNYouSLChenDSREVEAL-HBV Study Group: Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinomaJ Natl Cancer Inst10011341143200810.1093/jnci/djn24318695135

Flow diagram of the relevant studies included in the meta-analysis. HCV, hepatitis C virus.

Forest plot for the odds ratios of T1653 for the risk of HCC. HCC, hepatocellular carcinoma; CI, confidence interval; M-H, Mantel-Haensze.

Forest plot for the odds ratios of V1753 for the risk of HCC. HCC, hepatocellular carcinoma; CI, confidence interval; M-H, Mantel-Haensze.

Forest plot for the odds ratios of T1762/A1764 for the risk of HCC. HCC, hepatocellular carcinoma; CI, confidence interval; M-H, Mantel-Haensze.

Funnel plot regarding the publication bias of (A) T1653, (B) V1753 and (C) T1762/A1764 for the risk of hepatocellular carcinoma. OR, odds ratio; SE, standard error.

Characteristics and clinical data of the studies included in the meta-analysis.

Authors (year) Country Design Quality score E/C Age, years Gender (m/f) ALT level (U/l) HBV DNA (log copy/ml) HBeAg (+) patients (%) Genotype Mutation sites Detection method Refs.
Takahashi et al (1999) Japan PCC 6–10   58/271 NA NA NA NA   108 (37.6) C T1653, V1753, T1762, A1764, T1762/A1764 Sequencing (16)
Tanaka et al (2006) Japan/HK PCC ≥10 148/180 50.2±10.7 261/69 46 (8–773) 5.4±1.4   109 (33.2) C1, C2 T1653, V1753, T1762/A1764, V1765, A1896, A1899 Sequencing (17)
Shinkai et al (2007) Japan PCC ≥10 80/80 55±8 135/25   85±133 5.7±1.4   60 (37.5) C2 T1653, C1479, T1485, H1499, A1613, V1753, T1762/A1764, A1896 Sequencing (13)
Wang et al (2007) China PCC   ≤6   47/164 49.8±11.6 176/35 63.9±41.6 NA   112 (53.1) Ba, C1, C2 T1653, V1753, T1762/A1764, T1856, T1858, A1896, A1898, A1899 Sequencing (18)
Kim et al (2008) Korea PCC 6–10   60/124 45.9±17.3 134/50   90.8±132.1 NA   115 (62.5) C T1653, V1753, T1762/A1764 Sequencing (19)
Kim et al (2009) Korea PCC ≥10 135/135 44.3±7.9 224/46 NA 3.45±3.8   76 (28.1) C2 T1653, A1689, V1753, T1762/A1764, T1846, A1850, C1858, A1896 Sequencing   (6)
Choi et al (2009) Korea PCC   ≤6 42/46 57.3±9.3 57/31   89.8±110.5 6.2±1.5   39 (44.3) C2 M1385, A1485, B1499, B1574, A1613, T1631, T1653, V1753, T1762/A1764 Sequencing (20)
Tangkijvanich et al (2010) Thailand PCC ≥10 60/60 55.7±9.8 104/16 161.1±116.9 5.9±1.4 32 (30) B, C A1613, T1653, V1753, T1762/A1764, T1766/A1768, C1858C Sequencing (21)
Shi et al (2013) China PCC   ≤6 43/55 58.0±9.58 63/32 NA 4.67±0.91   46 (47.9) NA A1440, C1467, A1479, T1485, T1653, V1753, T1762/A1764 Sequencing (11)
Li et al (2013) China PCC 6–10 102/105 NA NA NA NA NA C2 T1653, V1753, T1762, A1764, T1766, A1768 Sequencing (22)
Lyu et al (2013) Korea PCC 6–10 318/234 55 (30–74) 452/100 37 (9–774) 4.09±2.39   271 (49.1) C2 T1653, V1753, T1762/A1764, A1896 Sequencing (23)

ALT, alamine aminotransferase; E/C, no. of experiments/no. of controls; HBeAg, hepatitis B e-antigen; HBV, hepatitis B virus; m/f, male/female; NA, not available; PCC, prevalence case-control.

Details of the quality criteria for studies included in the meta-analysis.

Score
Quality parameter 0 1 2
Study design Cohort or nested case-control Incidence case-control Prevalence case-control
Sample size of cases <50 50–100 ≥100
Source of samples None 1 hospital ≥2 hospitals
Mutation detection method None Others DNA sequencing
Matching of cases and controls
  (1) None Age or gender Age and gender
  (2) None HBeAg or genotype HBeAg and genotype

HBeAg, hepatitis B e-antigen.

Subgroup analyses based on the main characteristics of the included studies.

T1653 V1753 T1762/A1764
Characteristics T/P OR (95% CI) Model T/P OR (95% CI) Model T/P OR (95% CI) Model
HBeAg
  + 5/392 3.25 (1.87–5.66) Fixed 5/392 2.50 (1.52–4.12) Fixed 6/536 3.15 (2.03–4.89) Fixed
  − 5/741 2.56 (1.78–3.68) Fixed 5/741 1.84 (1.32–2.58) Fixed 6/911 5.50 (2.64–11.46) Fixed
Country
  China 3/513 3.23 (1.80–5.79) Fixed 3/513 5.17 (3.28–8.13) Fixed 3/513 5.99 (2.17–16.53) Random
  Japan 3/775 3.78 (1.52–9.41) Random 3/775 2.93 (2.11–4.06) Fixed 3/775 4.27 (2.68–6.80) Fixed
  Korea 4/1,094 2.50 (1.77–3.54) Fixed 4/1,094 1.25 (0.69–2.26) Random 4/1,094 3.58 (1.46–8.79) Random
  Thailand 1/120 2.75 (1.04–7.29) NA 1/120 2.51 (1.14–5.52) NA 1/120 6.19 (2.42–15.83) NA
Quality score
  >6 8/2,108 3.05 (2.10–4.42) Random 8/2,108 2.14 (1.39–3.28) Random 8/2,108 3.66 (2.30–5.81) Random
  ≤6 3/394 3.11 (1.74–5.59) Fixed 3/394 5.18 (2.98–9.02) Fixed 3/394 9.60 (5.14–17.93) Fixed

HBeAg, hepatitis B e-antigen; NA, not available; OR, odds ratio; T/P, no. of trials/no. of patients.